Uniqure NV News - UQ1

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment...

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s...

UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June

UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June ~ uniQure to host virtual Research & Development Day...

uniQure to Participate in Multiple Upcoming Industry Conferences in June

uniQure to Participate in Multiple Upcoming Industry Conferences in June ~ uniQure to host virtual Research & Development Day on June 22...

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s...

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease...

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to...

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector ~...

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress ~ 52-week follow-up data from HOPE-B pivotal...

uniQure announces closing of commercialization and license agreement with CSL Behring

uniQure announces closing of commercialization and license agreement with CSL Behring Upfront payment of $450 million due to uniQure by May...

uniQure to Participate in Multiple Upcoming Industry Conferences in May

uniQure to Participate in Multiple Upcoming Industry Conferences in May LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021...

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting LEXINGTON, Mass. and AMSTERDAM...

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26...

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in ...

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread...

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Hunti...

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Uniqure NV (UQ1)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

UQ1 News

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment...

UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June

uniQure to Participate in Multiple Upcoming Industry Conferences in June

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s...

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to...

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure announces closing of commercialization and license agreement with CSL Behring

uniQure to Participate in Multiple Upcoming Industry Conferences in May

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in ...

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Hunti...

uniQure to Participate in Multiple Upcoming Industry Conferences in April

uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program

uniQure Announces 2020 Financial Results and Highlights Recent Company Progress

UQ1 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Uniqure NV (UQ1) News

Uniqure NV (UQ1)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

UQ1 News

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment...

UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June

uniQure to Participate in Multiple Upcoming Industry Conferences in June

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s...

uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to...

uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress

uniQure announces closing of commercialization and license agreement with CSL Behring

uniQure to Participate in Multiple Upcoming Industry Conferences in May

uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in ...

uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Hunti...

uniQure to Participate in Multiple Upcoming Industry Conferences in April

uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program

uniQure Announces 2020 Financial Results and Highlights Recent Company Progress

UQ1 Discussion

Your Recent History